ArticleCell biology and toxicology2026
Mechanisms of synergistic action between olaparib and KPT-330 in pancreatic cancer.
Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPancreatic ductal adenocarcinoma (PDAC) is a highly aggressive and prognostically poor cancer driven by multifaceted mechanisms, notably immune evasion and drug resistance. The majority of PDAC patients present with unresectable locally advanced or metastatic disease, emphasizing a critical unmet need for effective therapies against advanced-stage pancreatic cancer. Despite the proven efficacy of the PARP inhibitor Olaparib against pancreatic cancer in patients carrying BRCA mutations, its practical use is limited by the development of acquired resistance. The clinical application of the PARP inhibitor Olaparib is limited by acquired resistance, making combination therapy a promising strategy to improve treatment responses. Exportin 1 (XPO1) is frequently overexpressed in PDAC cells, representing a therapeutic target, and its inhibitor KPT-330 has demonstrated antitumour potential. Therefore, we aim to combine Olaparib with KPT-330 to enhance its therapeutic effect against PDAC.
objectiveThis study aimed to investigate the synergistic antitumour effects of the combination of Olaparib and KPT-330 against PDAC and to elucidate the underlying molecular mechanisms.
methodsWe applied RNA sequencing to pancreatic cancer cell lines following combination therapy to identify differentially expressed genes. Separately, Western blotting was performed to measure both the expression and phosphorylation status of key proteins within the involved signaling cascades.
resultsThe combination of KPT-330 and Olaparib significantly suppressed PDAC cell viability and tumour growth. Mechanistic investigation revealed that the combination specifically reduced SGPP2 levels, leading to inhibition of the IL-6/JAK2/STAT3 signaling axis. Evidence included diminished p-JAK2 and p-STAT3, with no alteration in total JAK2 or STAT3. This SGPP2-associated synergistic effect may overcome olaparib resistance by modulating the immunosuppressive tumor microenvironment.
conclusionThis study reveals that the combination of Olaparib and KPT-330 enhances antitumor efficacy in pancreatic cancer by downregulating SGPP2, a tumor-associated protein, thereby inhibiting the IL-6/JAK2/STAT3 signaling pathway. SGPP2 is proposed as a key molecular node linking the two agents. Collectively, these findings provide preclinical evidence that the Olaparib and KPT-330 combination acts synergistically via the SGPP2/STAT3 axis, supporting its potential application in pancreatic cancer combination therapy.
Indexed as
Identifiers
42479102What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.